Cornell Pochily Investment Advisors Inc. Has $3.36 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cornell Pochily Investment Advisors Inc. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,335 shares of the medical research company’s stock after acquiring an additional 124 shares during the period. Thermo Fisher Scientific makes up approximately 1.4% of Cornell Pochily Investment Advisors Inc.’s investment portfolio, making the stock its 17th largest holding. Cornell Pochily Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $3,363,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Bornite Capital Management LP increased its position in Thermo Fisher Scientific by 50.0% during the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock worth $17,719,000 after buying an additional 10,000 shares during the last quarter. Fairfield Bush & CO. increased its stake in shares of Thermo Fisher Scientific by 1.2% in the first quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after buying an additional 36 shares during the period. Loomis Sayles & Co. L P grew its stake in Thermo Fisher Scientific by 563.5% during the first quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock worth $11,721,000 after purchasing an additional 16,853 shares during the period. Covestor Ltd grew its stake in Thermo Fisher Scientific by 60.5% during the first quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock worth $190,000 after purchasing an additional 121 shares during the period. Finally, Merit Financial Group LLC boosted its holdings in Thermo Fisher Scientific by 3.6% in the first quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock worth $395,000 after acquiring an additional 23 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last ninety days. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 0.1 %

Shares of Thermo Fisher Scientific stock traded down $0.35 during mid-day trading on Thursday, hitting $579.02. The stock had a trading volume of 157,742 shares, compared to its average volume of 1,603,173. The firm has a market cap of $220.79 billion, a P/E ratio of 37.50, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The firm has a 50-day moving average of $564.32 and a two-hundred day moving average of $519.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same period in the previous year, the company earned $5.40 EPS. The company’s revenue for the quarter was down 4.9% on a year-over-year basis. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be paid a $0.39 dividend. The ex-dividend date is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Analysts Set New Price Targets

TMO has been the topic of a number of recent research reports. Robert W. Baird restated an “outperform” rating and issued a $670.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Royal Bank of Canada boosted their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Citigroup began coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Finally, Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $599.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.